Last reviewed · How we verify
CXD101 in Combination With Nivolumab — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
CXD101 in Combination With Nivolumab (CXD101 in Combination With Nivolumab) — Celleron Therapeutics Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CXD101 in Combination With Nivolumab TARGET | CXD101 in Combination With Nivolumab | Celleron Therapeutics Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CXD101 in Combination With Nivolumab CI watch — RSS
- CXD101 in Combination With Nivolumab CI watch — Atom
- CXD101 in Combination With Nivolumab CI watch — JSON
- CXD101 in Combination With Nivolumab alone — RSS
Cite this brief
Drug Landscape (2026). CXD101 in Combination With Nivolumab — Competitive Intelligence Brief. https://druglandscape.com/ci/cxd101-in-combination-with-nivolumab. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab